Clinical Trial Search

Primary: Systolic Blood Pressure at Screening/Visit 1, Visit 2, and Visit 3 — 110.98; 110.63; 110.00 millimeters of mercury (mmHg) — p=>0.05

Primary: Effectiveness of Oxymetazoline in the Treatment of Rhinitis With Persistent Nasal Obstruction — 1.38; 1.67 units on a scale

Primary: Runny Nose as Measured by the Visual Analog Scale (VAS) at Baseline — 6.07 score on a scale

Primary: Change in Visual Analogue Scale for Major Nasal Symptoms — 3.66; 4.29; 4.49; 5.6 score on a scale

Primary: Cmax (the Maximum Observed Plasma Concentration) — 1630.223; 1729.393; 1617.810 ng/mL

Primary: Symptoms — 15.3; 11.3; 13.3; 9.8 Units on a scale

Primary: Daily Symptom Load — 1.25; 1.10; 1.32; 0.97 units on a scale

Primary: Eosinophilic Cationic Protein (ECP) Levels

Primary: Mean 24-hour Reflective Total 5 Symptoms Score (T5SS) Over the Total Treatment Period (14 Days) — 8.68; 7.87 points on a scale — p=<0.001

Primary: Mean 24-hour Reflective Total 5 Symptoms Score (T5SS) — 8.96; 8.77 points on a scale — p=0.546

Primary: Change From Diluent Challenge Contralateral Secretion Weight at Antigen Challenge — 6; 19.6 milligrams

Primary: Mean Change From Baseline (Pre-Dose) Twice Daily Averaged Subject-rated Reflective Total Nasal Symptom Score (TNSS) — -1.19; -1.58; -1.68; -1.63 score on a scale

Primary: Mean Major Symptom Complex (MSC) Score by Post-Treatment Evaluation Time Point (From 180 Minutes to 300 Minutes) — 7.4; 6.7; 8.5; 7.5 units on a scale

Primary: Change From Baseline Response in Albumin Levels in Nasal Lavage Following Each Challenge — -33.61; -82.2; -185.85; -41.87 ng/mL — p=>0.05

Primary: Allergic Rhinitis Symptom Score Including Rhinorrhea, Nasal Obstruction, Sneezing, Itchy Nose and Itchy Eyes at Week 4 — 2.82; 2.8; 1.19; 1.21 Unit Score